Drug Pricing: Page 5
-
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Lilly's new COVID-19 antibody becomes US' latest tool to battle omicron
The speedy clearance of Lilly’s bebtelovimab comes after the U.S. stopped distributing two of the company's earlier antibodies because they couldn't effectively neutralize the variant.
By Jonathan Gardner • Updated Feb. 11, 2022 -
Sarah Silbiger via Getty Images
FDA sends signal with tough questions of Lilly at cancer drug meeting
The agency criticized Eli Lilly for using a trial run in China to seek approval of an immunotherapy it licensed from Innovent Biologics. Outside advisers agreed in a decisive vote that could have repercussions for several other drugmakers.
By Jonathan Gardner • Feb. 10, 2022 -
Explore the Trendline➔
Elizabeth Regan / Industry Dive
TrendlineDrug pricing
Drug pricing legislation has put pharmaceutical companies on the defensive and created a new precedent for the industry.
By BioPharma Dive staff -
Lilly slows FDA submission of Alzheimer's drug after Medicare decision
Executives for the pharma downplayed the impact of an accelerated approval for donanemab, pointing to Medicare's plans to restrict coverage of Alzheimer's drugs like it to only patients in clinical trials.
By Jonathan Gardner • Feb. 3, 2022 -
Courtesy of EQRx
EQRx builds case for cancer drug it hopes can disrupt market
Study results show EQRx's drug, which it means to position as a lower-cost alternative to widely used cancer immunotherapies, extended the lives of lung cancer patients. But it's unclear whether that will be enough to sway the FDA.
By Kristin Jensen • Jan. 19, 2022 -
Permission granted by Biogen
Medicare faces blowback over plan to limit coverage of Biogen's Alzheimer's drug
Biogen, along with allies in industry, plans to pressure Medicare to water down its policy, which limits coverage of Aduhelm and drugs like it to clinical trials.
By Jonathan Gardner , Jacob Bell • Jan. 14, 2022 -
After years of decline, drugmakers' price hikes may have bottomed out
Inflation in 2021 may have offered drugmakers a catalyst for taking slightly bigger increases on a list price basis. But rebates to insurers are still keeping net price rises lower.
By Jonathan Gardner • Jan. 5, 2022 -
Permission granted by Biogen
New Alzheimer's drugs
After intense pushback, Biogen to cut price of Alzheimer's drug
Effective Jan. 1, the average list price for Aduhelm will drop about 50% to just over $28,000 a year. It's a move the company hopes will appease insurers and lower out-of-pocket costs for patients.
By Jacob Bell • Dec. 20, 2021 -
Mark Wilson via Getty Images
Martin Shkreli's former company to pay $40M in settlement over drug price hikes
The payment resolves the government's claims against Vyera and Phoenixus for their efforts to block competition to Daraprim, the toxoplasmosis drug Shkreli famously raised the price of by 4,000%.
By Kristin Jensen • Dec. 8, 2021 -
Win McNamee via Getty Images
As Congress weighs drug price restraints, ICER calls out 'unsupported' increases
In a new report, ICER highlighted AbbVie's price hikes on Humira, which the group said resulted in more than $1 billion in U.S. spending last year without any new evidence of health benefits.
By Jonathan Gardner • Nov. 16, 2021 -
Spencer Platt via Getty Images
Pfizer will allow generic drugmakers to produce promising COVID-19 pill
A licensing deal with a U.N.-backed patent group could expand supply of Pfizer's experimental drug Paxlovid in lower- and middle-income countries.
By Ned Pagliarulo • Nov. 16, 2021 -
Permission granted by Biogen
Anticipating Aduhelm's costs, Medicare plans big jump in premiums
While CMS is still weighing whether to authorize wide coverage of Biogen's pricey Alzheimer's drug, administrators are planning to build reserves in case costs skyrocket.
By Jonathan Gardner • Nov. 15, 2021 -
Megan Quinn/BioPharma Dive
Democrats’ drug pricing plan, while scaled back, could still squeeze pharma top-sellers
Legislation backed by President Joe Biden and top Democratic lawmakers would allow for price negotiation on 20 older drugs, potentially impacting blockbusters from Pfizer, Bristol Myers Squibb and others.
By Jonathan Gardner • Nov. 4, 2021 -
Adeline Kon / BioPharma Dive/BioPharma Dive
Deep Dive // Patent thicketsA three-decade monopoly: how Amgen built a patent thicket around its top-selling drug
Through high-stakes litigation, aggressive patenting practices and a bit of luck, Amgen will likely stretch Enbrel's monopoly until 2029, more than 30 years after it was approved.
By Jonathan Gardner • Nov. 1, 2021 -
Alex Wong via Getty Images
Drug price restraints dropped as Biden prioritizes other measures
Despite majority control of Congress, it appears unlikely the Biden administration will be able to pass meaningful pricing reform, though a slimmed-down bill may still be in the works.
By Jonathan Gardner • Oct. 29, 2021 -
Jon Cherry via Getty Images
J&J foresees end to not-for-profit sales of coronavirus vaccine
The drugmaker plans to switch over to a commercial business model late next year or early in 2023, said Jennifer Taubert, head of J&J's pharma division.
By Ned Pagliarulo • Oct. 19, 2021 -
Boehringer wins 'interchangeable' status for Humira copy, strengthening competitive threat
The interchangeable approval could help to boost adoption of Boehringer's biosimilar when it launches in mid-2023, a date set via settlement with AbbVie.
By Ned Pagliarulo • Oct. 18, 2021 -
Getty Images
Insurers sue Merck for 'monopolistic scheme' to delay generics of blockbuster cholesterol drug
The suits allege an agreement between Merck and a generic manufacturer kept low-cost versions of the drugmaker's widely used Zetia off the market for years.
By Samantha Liss • Sept. 24, 2021 -
Mark Wilson via Getty Images
Lilly, Novartis, other pharmas could face fines for violating 340B law
The U.S. health department asked its inspector general to review the refusals of six drugmakers to offer discounts to safety net hospitals through community pharmacy partnerships.
By Rebecca Pifer • Sept. 24, 2021 -
Alex Wong via Getty Images
Biden pushes forward on Medicare price negotiation
But opposition from the drug industry and congressional Republicans could make the Democrats' signature proposal an uphill battle.
By Jonathan Gardner • Sept. 10, 2021 -
Coherus, known for biosimilars, nears an immunotherapy battle with big pharma
New lung cancer results could make Coherus the next entrant in an ultra-competitive market dominated by pricey drugs like Merck's Keytruda.
By Ben Fidler • Aug. 19, 2021 -
Alex Wong via Getty Images
Biden embraces Medicare drug price negotiation as Democrats seek to widen health coverage
In a speech Thursday afternoon outlining his proposal, which features several familiar policy ideas, Biden emphasized price negotiation, but allowing for drugmaker profit.
By Jonathan Gardner • Updated Aug. 12, 2021 -
Permission granted by Biogen
VA leaves Aduhelm off coverage list, recommending against controversial Alzheimer's drug
The decision, which does provide for certain exceptions, is another bump in what's become a rocky market rollout for Biogen's medicine.
By Ned Pagliarulo • Updated Aug. 12, 2021 -
Getty Images
Startup EQRx to take drug price mission public through $1.8B SPAC deal
A merger with a blank-check company backed by Casdin Capital will greatly expand the resources available to EQRx, which aims to develop competitors to existing drugs and sell them at "radically lower" prices.
By Ned Pagliarulo • Aug. 6, 2021 -
Permission granted by Biogen
Questions on new Alzheimer's drug benefit, price loom large at ICER meeting
"Right now, and I think for a while, the access is going to be pretty limited," former CMS and FDA head Mark McClellan said at the meeting, which featured yet another rebuke by experts of Aduhelm.
By Ned Pagliarulo • July 16, 2021 -
Permission granted by Biogen
Medicare to weigh nationwide coverage rules for Biogen Alzheimer's drug
CMS will consider whether to set a single policy for Aduhelm, a process that could shape how millions of Americans access the controversial treatment.
By Ned Pagliarulo • Updated July 13, 2021
Previous
